| Chronic Lymphocytic Leukemia
Ruxience vs Zydelig
Side-by-side clinical, coverage, and cost comparison for chronic lymphocytic leukemia.Deep comparison between: Ruxience vs Zydelig with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZydelig has a higher rate of injection site reactions vs Ruxience based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zydelig but not Ruxience, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ruxience
Zydelig
At A Glance
IV infusion
CD20-directed cytolytic antibody
Oral
Twice daily
PI3K-delta inhibitor
Indications
- Lymphoma, Non-Hodgkin
- Chronic Lymphocytic Leukemia
- Rheumatoid Arthritis
- Granulomatosis with polyangiitis
- Microscopic Polyarteritis
- Pemphigus Vulgaris
- Chronic Lymphocytic Leukemia
Dosing
Lymphoma, Non-Hodgkin 375 mg/m2 IV; once weekly for 4 or 8 doses (relapsed/refractory), on Day 1 of each chemotherapy cycle for up to 8 doses (previously untreated follicular or DLBCL), or every 8 weeks for 12 doses as single-agent maintenance.
Chronic Lymphocytic Leukemia 375 mg/m2 IV on Day 1 of Cycle 1, then 500 mg/m2 IV on Day 1 of Cycles 2-6 in combination with fludarabine and cyclophosphamide, every 28 days.
Rheumatoid Arthritis Two 1,000 mg IV infusions separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks, in combination with methotrexate.
Granulomatosis with polyangiitis, Microscopic Polyarteritis Induction: 375 mg/m2 IV once weekly for 4 weeks; follow-up: two 500 mg IV infusions separated by 2 weeks, then 500 mg IV every 6 months based on clinical evaluation, in combination with glucocorticoids.
Pemphigus Vulgaris Two 1,000 mg IV infusions separated by 2 weeks plus tapering glucocorticoids; maintenance: 500 mg IV at Month 12 and every 6 months thereafter; relapse: 1,000 mg IV, no sooner than 16 weeks after the previous infusion.
Chronic Lymphocytic Leukemia 150 mg orally twice daily with or without food until disease progression or unacceptable toxicity; dose reductions to 100 mg twice daily apply after interruption for certain adverse reactions.
Contraindications
—
- History of serious hypersensitivity reactions to idelalisib, including anaphylaxis
- History of toxic epidermal necrolysis with any drug
Adverse Reactions
Most common (>=25%) Infusion-related reactions, fever, lymphopenia, chills, infection, asthenia (NHL); infusion-related reactions, neutropenia (CLL).
Serious Infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation with fulminant hepatitis, progressive multifocal leukoencephalopathy, tumor lysis syndrome, infections, cardiovascular adverse reactions, renal toxicity, bowel obstruction and perforation.
Postmarketing Prolonged pancytopenia, marrow hypoplasia, late-onset neutropenia, fatal cardiac failure, uveitis, optic neuritis, systemic vasculitis, pleuritis, lupus-like syndrome, serum sickness, polyarticular arthritis, vasculitis with rash, viral infections including PML, Kaposi's sarcoma progression, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease, PRES/RPLS.
Most common (>30%) Diarrhea, pneumonia, pyrexia, fatigue, rash, cough, nausea
Serious Hepatotoxicity, severe diarrhea or colitis, pneumonitis, infections (including sepsis, CMV, PJP), intestinal perforation, severe cutaneous reactions, hypersensitivity reactions, neutropenia
Postmarketing Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms
Pharmacology
Rituximab-pvvr is a chimeric monoclonal antibody that targets the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis through complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC).
PI3K-delta inhibitor; idelalisib blocks BCR, CXCR4, and CXCR5 signaling pathways to induce apoptosis and inhibit proliferation in normal and malignant B-cells, and reduces chemotaxis and adhesion of lymphoma cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ruxience
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (0/12)
Zydelig
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Ruxience
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zydelig
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Ruxience
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Zydelig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Ruxience Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Zydelig Access Connect Copay Coupon CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RuxienceView full Ruxience profile
ZydeligView full Zydelig profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.